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introduction: In a literature meta-analysis, we showed survival benefits for regimens 
including cisplatin [hazard ratio (HR) 0.61; 95% confidence interval (CI), 0.57–0.66] and 
for those including etoposide (HR 0.65; 0.61–0.69). That benefit was mainly observed 
when etoposide alone or in combination with cisplatin was included in the chemotherapy 
regimens. Our objective was to determine if chemotherapy with both drugs improves 
survival in comparison to a non-platinum regimen with etoposide.
Methods: Extensive small-cell lung cancer patients were randomized between cisplatin–
etoposide (CE) and ifosfamide + etoposide + epirubicin regimen (IVE) between 2000 and 2013.
results: 176 and 170 eligible patients were allocated to CE and IVE (315 deaths were 
required before analysis), respectively. Objective response rates were not significantly 
different: 60% with CE and 59% with IVE. No statistically significant difference in median 
survival and 1-year and 2-year was observed with rates of 9.6 months, 31 and 5% for 
CE and 10 months, 39 and 9% for IVE, respectively. HR was 0.84 (95% CI 0.68–1.05, 
p = 0.16). Only two prognostic factors for survival were retained in multivariate analysis: 
sex with HR = 0.69 (95% CI 0.49–0.97, p = 0.03) and performance status with HR = 0.53 
(95% CI 0.49–0.97, p < 0.0001). After adjustment for these prognostic factors, HR for 
survival was 0.83 (95% CI 0.65–1.08, p = 0.17). There was more thrombopenia in the 
CE regimen and more leukopenia with IVE.
Conclusion: Combination of CE failed to improve survival in comparison to an etopo-
side-containing regimen without cisplatin.
Clinical Trial registration: https://clinicaltrials.gov/ct2/show/NCT00658580?term= 
ELCWP+01994&rank=1, identifier NCT00658580.
Keywords: small-cell lung cancer, chemotherapy, cisplatin, etoposide, extensive disease
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inTrODUCTiOn
Introduction of chemotherapy in the treatment of small-cell 
lung cancer (SCLC) modified significantly the prognosis of those 
patients, not only by achieving impressive objective response rates 
but also by impacting deeply on overall survival. Despite these 
achievements, few patients will be cured with a 5-year overall 
survival below 5% (1). Higher cure rates are obtained in patients 
with limited disease (LD) compared to those with extensive or 
metastatic disease (ED), LD being a strong prognostic factor (2).
Standard treatment for extensive disease, a disease where 
lesions cannot be encompassed in a single radiotherapy field, 
consists in combination chemotherapy. There remains discussion 
about the most active chemotherapy regimen. In the late 1990s 
when designing this trial, Americans mainly recommended 
“cisplatin (CDDP) and etoposide (VP16)” based-regimens and 
Europeans “cyclophosphamide–adriamycin–etoposide” based-
combinations. Each regimen showed a differential toxicity profile 
with increased renal and neurological impairment in cisplatin-
containing regimens and more cardiotoxicity with anthracycline 
derivatives.
As there was no valuable randomized trial comparing 
these so-called standard regimens, our cooperative group, the 
European Lung Cancer Working Party (ELCWP), performed 
a meta-analysis of the literature on the topic (3). 36 published 
randomized trials during the period 1980–1998 comparing first-
line regimens were identified. They were grouped according to 
the regimen comparisons: CDDP-based regimen versus chemo-
therapy without CDDP or VP16 (group 1; 1 trial), VP16-based 
regimen without CDDP versus chemotherapy without VP16 
(group 2; 17 trials), CDDP  +  VP16 versus a regimen without 
both drugs (group 3; 9 trials), and CDDP + VP16 versus a VP16 
only regimen (group 4; 9 trials). Combined hazard ratios (HRs) 
were as follows: 0.70 [95% confidence interval (CI) 0.41–1.21] 
for group I, 0.73 (95% CI 0.67–0.78) for group II, 0.57 (95% CI 
0.51–0.64) for group III, and 0.74 (95% CI 0.66–0.83) for group 
IV. Those data showed better effectiveness for the combination 
of cisplatin and etoposide, while improved survival was also 
observed separately for CDDP (HR = 0.61, 95% CI: 0.57–0.66) 
and for VP16 (HR = 0.65, 95% CI: 0.61–0.69).
Robustness of the results of that meta-analysis had to be 
confirmed by randomized trials. The purpose of the present trial 
was thus an attempt to confirm in terms of overall survival the 
superiority of the cisplatin + etoposide (CE) combination over 
an etoposide-containing regimen without cisplatin as often used 
in Europe. We have chosen the CE regimen as used in LD (4) and 
the IVE regimen with ifosfamide, epirubicin, and etoposide as 
shown in our prior trials (5). The ELCWP has shown that epiru-
bicin is associated with better cardiac tolerance than adriamycin 
when combined to ifosfamide and etoposide (6).
PaTiEnTS anD METHODS
Eligibility Criteria
To be eligible, patients with pathologically proven SCLC [using 
World Health Organization (WHO) classification] had to pre-
sent with ED, defined as a disease with distant metastases or as 
a locoregional disease that could not be locally treated within 
a single radiotherapy field. Other inclusion criteria were as 
follows: no prior therapy (radiotherapy, chemotherapy, or sur-
gery), Karnofsky performance status (PS) of at least 60, presence 
of an assessable lesion, no history of prior malignant tumor except 
non-melanoma skin cancer or in  situ carcinoma of the cervix 
or a cured cancer (defined as a disease-free interval > 5 years), 
adequate hematological (WBC count ≥ 4,000 mm3 and platelet 
count ≥  100,000  mm3), renal (serum creatinine <  1.3  mg/dl) 
and hepatic (serum bilirubin < 1.5 mg/dl) functions, no recent 
myocardial infarction (<3  months before date of diagnosis), 
no congestive cardiac failure and cardiac arrhythmia requiring 
medical treatment, no uncontrolled infectious disease, and 
no other serious medical or psychological factors that might 
prevent adherence to the treatment schedule. Patients with 
brain metastases can be included provided that they satisfied 
to the other inclusion criteria. Patients had to be accessible for 
follow-up and to provide informed consent. Study protocol 
was approved by the ethical committee of each participating 
institution.
Therapeutic Schedule
Eligible patients were randomized between the CE regimen 
[cisplatin (90 mg/m2 d1) plus etoposide (100 mg/m2 d1 to 3)] 
and the ifosfamide  +  etoposide  +  epirubicin regimen [IVE: 
epirubicin (60 mg/m2 d1) plus etoposide (100 mg/m2 d1 to 3) 
plus ifosfamide (1.5 g/m2 d1 to 3)]. All drugs were intravenously 
(iv) administered. Cisplatin was given over 30 min in 250 ml 
NaCl 3%, after prehydration with 1,000 ml of 5% dextrose in 
0.45% NaCl for 4 h and followed by a mannitol induced diu-
resis (12.5  g of mannitol injected as an iv bolus immediately 
prior to cisplatin administration and then as a continuous 20% 
solution 60  ml/h for the next 6  h) and a posthydration with 
4,000 ml of 5% dextrose in 0.45% NaCl with 1.5 g KCl/l for the 
next 24 h. Diuresis and emesis had to be measured every 6 up 
to 24 h thereafter and if urine output decreased to <75 ml/h, 
furosemide (40 mg) had to be administered iv. Etoposide was 
diluted in 250  ml NaCl 0.9% and infused over 1  h, just after 
cisplatin administration. Epirubicin was given as a short infu-
sion before etoposide. Ifosfamide was diluted in 1 l NaCl 0.9% 
and administered iv over 3 h. Mesna was infused at a dose of 
300 mg/m2 just before ifosfamide and then every 4 for 72 h.
Cycles were repeated every 3 weeks, with response evaluation 
after the three first ones. In case of no response, patients went off 
treatment. In case of response, chemotherapy was administered 
until complete response or unacceptable toxicity or best response, 
defined as non-improved response by three further courses of 
chemotherapy. Response had to be assessed every three cycles. 
At relapse, if the delay since the last chemotherapy cycle was 
more than 6 months, the same chemotherapy regimen as initially 
was given again. Otherwise, patients were off trial. Prophylactic 
cranial irradiation was not mandatory in the study.
The dose reduction plan for the drugs was as follows: in 
case of serum creatinine peak above 2.0  mg/dl, cisplatin or 
ifosfamide has to be reduced to 50% of initial dosage. If serum 
creatinine on day 1 of new course was >1.5  mg/dl, cisplatin 
was omitted and ifosfamide dosage reduced by 50%. If the 
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granulocytes or platelets nadir was, respectively, less than 500/
mm3 or 25,000/mm3, drugs were to be given at 75% of the initial 
dosage. In case of any new cardiac problem, epirubicin was 
stopped. Failure to recover from myelosuppression (neutro-
phils < 1,500/mm3 or platelets < 100,000/mm3) by day 36 was 
reason for discontinuation of treatment There was no upward 
dose modification.
Workup
The initial workup consisted of a complete history and physical 
examination, chest X-ray and computed tomography (CT) scan, 
fiberoptic bronchoscopy with biopsy, bone scintigraphy with 
X-rays of suspected areas, bone marrow biopsy, liver and adrenals 
CT scan or echography, brain nuclear magnetic resonance or CT 
scan, blood chemistries including complete blood cell counts, 
electrolytes, serum creatinine and liver function tests, ECG, and 
echocardiogram or isotopic left ventricular ejection fraction. 
Blood chemistries, chest X-ray, and clinical examination were 
repeated before each course. Restaging, including all tests per-
formed during the initial workup (except for bronchoscopy), was 
repeated every three courses. After discontinuation of therapy, 
patients were assessed every 2  months for 6  months and then 
every 3 months by clinical examination, blood chemistries, and 
chest X-ray.
Evaluation Criteria
Patients were considered evaluable for response if they had com-
pleted three courses of chemotherapy. Responses were evaluated 
during regular meetings of the group by at least three independent 
observers. Complete remission was defined as the disappearance 
of all signs of disease for at least 4 weeks. In measurable disease, 
partial response (PR) consisted of a 50% or greater decrease of 
the sum of the products of the two greatest diameters of all meas-
urable lesions as established by two observations not less than 
4 weeks apart and without the appearance of new lesions or pro-
gression of any lesion. Patients with unidimensionally measurable 
lesions were considered to have evaluable disease. In evaluable 
disease, PR was defined as an estimated decrease in tumor size 
of 50%. Progression was defined as an increase of >25% in one or 
more measurable or evaluable lesions or the appearance of new 
lesions. All other circumstances were classified as “no change”. 
Patients with early death due to progression of the disease before 
any evaluation, those with early disease progression before evalua-
tion, and those with toxic death or early treatment discontinuation 
due to chemotherapy were considered evaluable.
Progression-free survival (PFS) and survival times were 
calculated from the day of randomization until the first event, 
progression, or death for the first item and death for the second 
item. World Health Organization criteria were used to assess 
toxicity.
Statistics
Randomization was stratified by center, Karnofsky PS (≤70 ver-
sus ≥80), presence of metastatic disease or not, and neutrophil 
count (≤ versus >7,500/mm3). The procedure was centralized 
and computerized. Randomization algorithm used the minimiza-
tion technique (7). Treatment assignment was obtained by calling 
the study data manager. The ELCWP central office for the study 
coordination and analysis (including the study coordinator, the 
biostatistician and the data manager) was located at the Jules 
Bordet Institute in Brussels.
The primary end point of the trial was survival. On the basis 
of the systematic review performed by the Group (3), regimens 
based on cisplatin and etoposide could improve patients’ 
survival compared to regimens including etoposide but not 
cisplatin. The benefit in favor of the two drugs was expressed in 
terms of an HR that was estimated to be 0.70. Our aim was to 
have a clinical trial able to detect that the HR of death between 
two such regimens was different from 1 in case its true value is 
0.70 (for a patient treated with both drugs compared to a patient 
receiving a regimen based on etoposide only). Fixing the HR is 
enough to calculate the number of events required to have the 
planned statistical power. So, we did not search to translate the 
HR into an absolute difference. However, assuming a median 
survival of 10 months in the IVE regimen, an HR of 0.70 in favor 
of CE translates into a median survival of about 14 months. Such 
an HR should be detectable with a power of 80% using a test 
level of 5%. To achieve this objective, we needed to observe an 
overall number of events (deaths) of 315. Assuming that 90% 
of the patients will be followed until death, this requirement 
was equivalent to the randomization of 175 patients per arm in 
the study. Secondary end points were response and toxicity. No 
interim analysis for survival or response was done.
Survival curves were estimated by the method of Kaplan and 
Meier. The log rank test was used to compare survival curves. 
p-Values for testing differences between proportions were calcu-
lated with chi-square tests or with Fisher’s exact tests. A multi-
variate analysis for adjustment of the treatment effect taking into 
account prognostic factors was carried out for survival by fitting 
the data with Cox models. Statistical results were considered as 
significant when the p value was <0.05. All reported p values are 
two-sided.
The evaluation of chemotherapy intensity was performed by 
the calculation of two dose-related variables. The relative dose-
intensity (RDI) was defined, for each drug, by the ratio of the 
received dose divided by the scheduled dose to the actual duration 
of treatment divided by the scheduled duration. The total RDI 
was the mean of the RDIs of all the drugs. The RDI was expressed 
as the percentage of the projected intensity. The absolute dose-
intensity expressed in mg/m2/3  weeks was defined as the ratio 
of the received dose to the actual duration of treatment; it was 
analyzed for etoposide. All of the formulae have been published 
in a prior report (8). Using Mann–Whitney tests, comparisons of 
the distributions of the dose intensity variables between regimens 
were done.
rESUlTS
A total of 361 patients were randomized from May 2000 to May 
2013. Fifteen were not eligible, 4 in the CE arm (2 by history of 
another cancer and 2 by lack of data), and 11 in the IVE arm 
(2 by history of another cancer, 2 by lack of data, 3 by wrong 
histology, 1 because of LD, 1 by increased bilirubinemia, 1 by 
incomplete initial workup, and 1 by major protocol violation). 
TablE 2 | Antitumor response assessment.
response at 3 cycles CE iVE
N patients 176 170
Complete response 2 (1%) 2 (1%)
Partial response 103 (59%) 98 (58%)
No change 9 (5%) 12 (7%)
Progression 21 (12%) 19 (11%)
Early death by cancer 5 (3%) 6 (4%)
Early death by toxicity 18 (10%) 10 (6%)
Death due to tumor necrosis 1 (1%) 3 (2%)
Stop for toxicity 10 (6%) 3 (2%)
Stop by patient for toxicity 1 (1%) 1 (1%)
Inevaluable 6 (3%) 16 (9%)
CE, cisplatin + etoposide regimen; IVE, ifosfamide + etoposide + epirubicin regimen.
TablE 1 | Characteristics of the eligible patients.
Characteristics CE (n = 176) iVE (n = 170)
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FigUrE 1 | Consort diagram.
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Of the 346 eligible patients, 176 were allocated to the CE arm 
and 170 eligible to the IVE arm (Figure 1, CONSORT diagram). 
Their characteristics are shown in Table 1. Both arms were well 
balanced. Median follow-up duration of the patients at the time 
of analysis was 113  months (range: 4–169). There were 329 
deaths. Among the 17 patients alive, 9 are lost to follow-up.
Forty-seven percentage of the patients in each arm received six 
cycles of chemotherapy; 8 and 10% receiving more cycles (up to 9) 
in the CE and IVE arms, respectively (p = 0.66). Dose reductions 
involved 43 and 54% of the patients, respectively (p = 0.07). In 
terms of dose-intensity, there was no significant difference for 
RDI with respective median values of 0.80 and 0.76 for the whole 
chemotherapy (p  =  0.13) and of 0.79 and 0.77 for etoposide 
(p =  0.34). The median weekly dose of etoposide received was 
79 and 77  mg/m2/week for the CE and IVE arms, respectively 
(p = 0.34).
Twenty-two patients were not assessable for response: 6 in the 
CE arm (no treatment given in 2, 1 lost to follow-up, 1 sudden 
death, 1 no workup for evaluation, 1 treatment stop due to tuber-
culosis), and 16 in the IVE arm (6 no treatment given, 4 major 
protocol violation, 3 early death unrelated to cancer or treat-
ment, 1 lost to follow-up, 1 workup refusal, and 1 sudden death). 
Table 2 shows the evaluation of response to chemotherapy. Two 
additional responses (one in each arm) were observed after the 
first three cycles of chemotherapy later. Best objective responses 
rates (intent to treat analysis) were 106 patients/176, 60% (95% 
CI 53–68%) for CE and 101/170, 59% (95% CI 52–67%) for IVE 
(p = 0.88), respectively.
The number of documented progressions was 251; 89 patients 
died without documentation of progression. In those 89 patients, 
death was considered cancer-related by the local investigator but 
FigUrE 2 | Overall survival curves according to treatment arm (arm 1 = CE; arm 2 = IVE). CE, cisplatin + etoposide regimen; IVE, ifosfamide + etoposide + epirubicin 
regimen; MST, median survival time; CI, confidence interval; m, month; HR, hazard ratio.
TablE 3 | Univariate analyses of prognostic factors for survival.
Variable Hr 95% Ci p-Value
Age (continuous evaluation) 1.02 1.01–1.04 0.002
Staging (ref = LD) 1.38 0.94–2.04 0.10
Sex (ref = male) 0.69 0.52–0.91 0.008
Karnofsky (ref ≤ 70) 0.60 0.46–0.78 0.0001
Weight loss (ref ≤ 5%) 1.28 1.00–1.64 0.05
Neutrophil count (ref ≤ 75%) 1.42 1.11–1.82 0.006
Neutrophil count (ref ≤ 7,500) 1.46 1.14–1.86 0.003
WBC count (ref = ≤ 100,00) 1.23 0.98–1.54 0.08
HR, hazard ratio; CI, confidence interval; LD, limited disease.
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no progression was formally documented by radiological inves-
tigations in 16 cases; 22 patients died from infection eventually 
related to neutropenia, 9 died from cardiovascular events, 12 died 
from early death by cancer or bleeding due to tumoral necrosis, 
no cause can be documented in 24 patients while the 6 latter 
died from digestive (n = 2), renal (n = 2), respiratory (n = 1), 
or neurolo gical (n = 1) events. There was no significant difference 
between arms in terms of documented progression, primary 
progression, and secondary progression within 3  months after 
treatment stop or after more than 3 months after treatment stop. 
Median PFS for CE and IVE was5.1  months (95% CI 4.8–6.2) 
and 5.3 months (95% CI 4.7–6.2), respectively, with 1-year rates 
of 10% (95% CI 5–15%) and 7% (95% CI 3–11%) and 2-year rates 
of 2% (95% CI 0–4%) and 3% (95% CI 0–6%).
There was no statistically significant difference in overall 
survival according to treatment arm (Figure  2). 169 and 160 
deaths were observed with CE and IVE, respectively. Median 
overall survival and survival rates at 1 year and at 2 years were 
(with 95% CI) 9.6 months (8.6–10.4) and 10 months (8.9–11.5), 
31% (24–38%) and 39% (27–41%), and 5 (1–9%) and 9% (4–14%) 
(p = 0.16), respectively. HR for treatment arm (taking CE as refer-
ence) was 0.84 (0.68–1.05).
The univariate analyses of prognostic factors for survival are 
detailed in Table 3. Four were significantly associated with sur-
vival age (p = 0.002), sex (p = 0.008), Karnofsky PS (p = 0.0001), 
and neutrophil count (p = 0.006). In multivariate analysis, only 
two were statistically significant: sex with HR  =  0.69 (95% CI 
0.49–0.97) (p = 0.03) and PS with HR = 0.53 (95% CI 0.49–0.97) 
(p < 0.0001). After adjustment for the prognostic factors, HR for 
treatment arm was 0.83 (95% CI 0.65–1.08), p = 0.17.
Hematological and non-hematological toxicities are described 
in Tables 4 and 5, respectively. There was more leukopenia with 
IVE and more thrombopenia and nausea and vomiting with CE. 
Toxic deaths occurred in 28 patients: 17 in the CE arm and 11 
in the IVE arm. Causes were, in the CE arm, complicated febrile 
neutropenia (8), cardiovascular complications (4), septic shock 
(2), colic perforation related to steroids administration (1), 
sudden death (1), and bleeding due to tumor necrosis (1). They 
were for IVE complicated febrile neutropenia (5), sudden death 
(2), septic shock (1), respiratory failure (1), renal failure (1), and 
vascular complication (1).
DiSCUSSiOn
Our randomized clinical trial (RCT) failed to confirm in terms 
of overall survival the superiority of the CE combination over an 
etoposide-containing regimen without cisplatin as suggested by 
TablE 5 | Non-hematological toxicity analysis.
Toxicity Evaluable grade iii/iV Evaluable grade iii/iV p
CE iVE
Nausea/vomiting 154 17 (11%) 155 8 (5%) 0.06
Diarrhea 153 3 (2%) 155 0 0.08
Skin toxicity 152 – 152 – –
Infection 156 18 (12%) 155 23 (15%) 0.39
Bleeding 152 2 (1%) 153 1 (1%) 1
Neurological 149 3 (2%) 154 – 0.24
Urinary 152 – 153 –
Hear loss 152 – 153 –
Nephrotoxicity 156 3 (2%) 154 2 (1%)
Stomatitis 151 1 (1%) 155 2 (1%)
Respiratory 151 3 (2%) 154 10 (6%) 0.10
Cardiac 153 6 (4%) 153 2 (1%) 0.28
Alopecia 151 65 (43%) 152 64 (42%) 0.96
CE, cisplatin + etoposide regimen; IVE, ifosfamide + etoposide + epirubicin regimen.
TablE 4 | Hematological toxicity analysis.
leukopenia, p < 0.0001 Evaluable 0 i ii iii iV
CE 174 26 (15%) 30 (17%) 45 (26%) 42 (24%) 31 (18%)
IVE 165 22 (13%) 4 (2%) 28 (17%) 58 (35%) 53 (32%)
Thrombopenia, p < 0.001 Evaluable 0 i ii iii iV
CE 174 86 (49%) 20 (11%) 30 (17%) 23 (13%) 15 (9%)
IVE 165 114 (69%) 16 (10%) 15 (9%) 12 (7%) 8 (5%)
CE, cisplatin + etoposide regimen; IVE, ifosfamide + etoposide + epirubicin regimen.
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our meta-analysis (3). From a clinical point of view, our results 
do not support clinical practice guidelines recommending 
platinum–etoposide regimens as the unique chemotherapy 
reference for first-line treatment of ED SCLC. From a meth-
odological point of view, the study emphasizes the necessity of 
ad  hoc controlled trials to validate meta-analysis results before 
implementation in the daily practice.
The strongest strength of our RCT is its completion with 
a strict respect of the statistical considerations. We did not 
perform any preliminary analysis before reaching the number 
of required events. This explains in part why we had to wait so 
long before presenting the results in addition to a progressive 
relative reduction in SCLC epidemiology. Nevertheless, during 
this time period standard therapeutics for ED SCLC remained 
globally unchanged in European countries (irinotecan being 
used in Far East countries) as well as workup procedures. 
Despite modifications in the TNM classification, our definition 
of ED is well validated and conserved its operational value at 
the difference of the TNM staging that mainly has prognostic 
significance.
Another advantage of the study is to be purely academic 
and is not disturbed by any commercial considerations. As 
regimens, we chose those we routinely used in our trials and 
practice in 1990s. We had nevertheless to face the problem of 
a slower accrual than expected, precisely due to the academic 
character of the study. Even if the protocol was approved by 
the ethical committees and the patients accrual started before 
the European directive on good clinical practice in the conduct 
of clinical trials on medicinal products for human use, the 
burden of its administrative consequence had a psychological 
effect on the investigators of our Group, some becoming more 
and more reluctant to propose their patients to participate to 
therapeutic studies. This negative effect is well discussed in 
the literature (9), and the directive needs to be improved to 
facilitate academic research. Nevertheless, today, the conduct 
of a trial like the presently reported one is very difficult for 
clinicians because of lack of financial, administrative, and man-
aging resources to face all the bureaucratic constraints resulting 
from the directive.
Discrepancy between meta-analysis and subsequent RCT is 
well documented in the literature in various medical disciplines, 
even when the trials are very large (10–13). Some methodologists 
recommend large-scale randomized studies to provide adequate 
evidence for clinical decision, without undue emphasis on small 
size trials, meta-analysis, and subgroup analysis (14). It can be 
argued that our study is not large enough. The statistical con-
siderations have been calculated to answer to the question with 
a sufficient power and a clinical significance. For SCLC, a trial 
including around 350 patients is not to be considered small, when 
compared to most recent studies (15) and in the present case, 
the required number of patients was reached to allow answering the 
question according to considerations defined prior to starting 
the enrollment of patients.
Other meta-analyses are available in the literature for first-
line chemotherapy in ED SCLC. None deals with our topic. 
Pujol et al. (16) conducted a meta-analysis of randomized trials 
of a cisplatin-containing regimen versus a regimen without this 
alkylating agent. The role of etoposide has not been specifically 
TablE 6 | Summary of randomized trials comparing a platinum–etoposide regimen to an etoposide combination in small-cell lung cancer patients.a
reference Disease extent N Schedules 1-year survival 2-year survival
Baka et al. (23) LD/ED 280 (114 ED) ACE
PE
RR 0.9 (95% CI 0.39–2.10) RR 4.51 (95% CI 0.22–91.86)
Gatzemeier et al. (24) ED 317 CEV
EV
RR 1.10 (95% CI 0.85–1.43) RR 1.01 (95% CI 0.60–1.71)
Sculier et al. (25) LD/ED 201 (102 ED) PEVs
EVs
RR 0.77 (95% CI 0.54–1.08)b RR 0.84 (95% CI 0.37–1.90)b
Urban et al. (26) LD/ED 457 (360) ACE
ACE-P
RR 1.10 (95% CI 0.81–1.50)b RR 1.00 (95% CI 0.44–2.25)b
Wolf et al. (27) LD/ED 141 (87 ED) PE
IE
RR 1.29 (95% CI 0.62–2.69) RR 0.67 (95% CI 0.16–2.81)
aAdapted from Cochrane 2015 (22).
bResults are for combined LD and ED patients.
LD, limited disease; ED, extensive or metastatic disease; ACE, adriamycin, cyclophosphamide, etoposide; PE, cisplatin, etoposide; RR, relative risk; CEV, carboplatin, etoposide, 
vincristine; EV, etoposide, vincristine; PEVs, cisplatin, etoposide, vindesine; EVs, etoposide, vindesine; P, cisplatin; IE, ifosfamide, etoposide.
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assessed. The authors concluded to an advantage for using 
cisplatin-based chemotherapy. Two other groups have com-
pared CE to cisplatin plus irinotecan (17), irinotecan–platinum 
with etoposide (18, 19) or CE to other platinum-based regimens 
(20), without showing a superiority of a particular except 
perhaps cisplatin plus irinotecan, especially in Far East popula-
tions. But again, the specific effect of etoposide has not been 
investigated in this study. The COCIS meta-analysis (21) of 
individual patient data, comparing carboplatin—or cisplatin—
based chemotherapy, did not cover our present topic about the 
role of etoposide. More recently, a Cochrane meta-analysis (22) 
looked at the effect of platinum administration versus non-
platinum combinations. No improvement in terms of 6, 12, and 
24  months survival was noted. Despite the specific questions 
of adding cisplatin to etoposide versus an etoposide without 
cisplatin regimen was not addressed, this meta-analysis add to 
the questioning of the use of platinum derivatives for first-line 
treatment of ED SCLC.
Excluding alternating regimens, five other randomized trials 
(23–27) presented with some similarities with our trial. These are 
summarized in Table 6. Only one included exclusively ED SCLC 
(24) and for two studies, it was not possible obtaining separate 
data for ED. Regimens were heterogeneous and in two studies, 
carboplatin was allowed or the only platinum compound. None 
of the trials showed improvement in terms of 12- and 24-month 
survival by adding a platinum derivative to etoposide. The data 
are also opening the question of the type of platinum deriva-
tive to be used in addition to etoposide. Few randomized trials 
have been published on this topic in SCLC. An individual data 
meta-analysis published in 2012, including a limited number of 
patients, showed no difference in terms of overall survival and 
PFS between carboplatin- and cisplatin-containing regimens 
while a differential toxicity profile with more hematological 
toxicities with carboplatin and non-hematological ones for 
cisplatin (21).
Our RCT results have implication for guidelines in the man-
agement of SCLC. Today, clinical practice guidelines recommend 
for ED the administration of a platinum-based chemotherapy 
with etoposide in America by the American College of Chest 
Physicians (CHEST) (28, 29) and by the American Society 
of Clinical Oncology endorsing CHEST (30) and in Europe 
by the European Society of Medical Oncology (31) endorsed by 
the Japanese Society of Medical Oncology or by our own group, 
the ELCWP (15). For LD, the data for supporting the admin-
istration of CE are very consistent because almost all the RCTs 
with radiochemotherapy have used that regimen, mainly for 
radiosensitization purposes. But for ED, the scientific evidence 
is supported by the two meta-analyses, by Pujol et al. (16) and 
by our group (3). All agree that there is no clear survival benefit 
in favor of platinum-derivative regimens with etoposide. The 
main argument for this recommendation is a better tolerance. 
The choice between cisplatin and carboplatin is still open and 
the lack of benefice when irinotecan is substituted to etoposide 
is emphasized.
Finally, we can discuss about the optimal duration of chemo-
therapy in ED SCLC. Numerous trials assessed prolongation of 
chemotherapy above four to six cycles but with very heterogene-
ous designs precluding meaningful conclusions. In the present 
study, 8–10% of the patients received up to nine cycles but the 
majority had no more than six cycles. We can expect that pro-
longing chemotherapy duration may expose the patient to more 
adverse events. As there is no high level evidence on the optimal 
number of chemotherapy cycle, prolonging treatment above six 
cycles should be an individual decision taking into account the 
potential benefit and the risk of toxicity.
In conclusion, according to our meta-analysis (3) but not 
previous meta-analysis results (3, 16), this original, large, and 
specifically designed for ED SCLC, randomized, controlled trial 
showed that the CE combination failed to improve survival in 
comparison to an etoposide-containing regimen without cispl-
atin. These data weaken the evidence supporting the currently 
available guidelines for the management of ED SCLC and may 
suggest updating them according to our results.
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